Spiriva Respimat (tiotropium bromide) / Boehringer Ingelheim - LARVOL DELTA

Efficacy of Intermittent Tiotropium in Early Childhood Wheezing (clinicaltrials.gov) - P4 | N=80 | Terminated | Sponsor: Helsinki University Central Hospital | Completed ➔ Terminated; Subjects in the Salbutamol group discontinued the intervention more often due to troublesome respiratory symptoms

Trial termination • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

Comparison table: Inhaled drugs for treatment of COPD. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases

Drugs for COPD. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections • Tobacco Cessation

Boehringer Ingelheim's COPD and asthma inhalers are now available for $35 a month for eligible patients (PRNewswire) - "Boehringer Ingelheim's new program to cap out-of-pocket costs at $35 per month for eligible patientsi for the company's inhalers is now available. The program applies to all Boehringer Ingelheim inhalers, including: Atrovent HFA (ipratropium bromide HFA) Inhalation Aerosol. Combivent Respimat (ipratropium bromide and albuterol) Inhalation Spray. Spiriva HandiHaler (tiotropium bromide inhalation powder). Spiriva Respimat 1.25 mcg (tiotropium bromide) Inhalation Spray. Spiriva Respimat 2.5 mcg (tiotropium bromide) Inhalation Spray. Stiolto Respimat (tiotropium bromide and olodaterol) Inhalation Spray. Striverdi Respimat (olodaterol) Inhalation Spray."

Pricing • Asthma • Chronic Obstructive Pulmonary Disease

Effects of Acute Long-acting Bronchodilation on Oxygenation and Peripheral Ventilation in COPD (clinicaltrials.gov) - P3 | N=30 | Completed | Sponsor: Erasme University Hospital

New P3 trial • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases

Tiotropium Handihaler vs. Tiotropium Respimat in COPD (clinicaltrials.gov) - P2 | N=0 | Withdrawn | Sponsor: Duke University | N=25 ➔ 0 | Not yet recruiting ➔ Withdrawn

Enrollment change • Trial withdrawal • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases

"Can you help me to make order on line with Spiriva Respimat 2.5. For urgant i live at saudi arabia" (@fady62086615)

Lupin Announces Health Canada Approval of Tiotropium Bromide Inhalation Powder for Treatment of COPD (Lupin Pharmaceuticals Press Release) - "Global pharma major Lupin Limited (Lupin) announced today that its Canada subsidiary, Lupin Pharma Canada Ltd., has received approval from Health Canada to market a generic version of Spiriva® (tiotropium bromide inhalation powder) for the treatment of chronic obstructive pulmonary disease (COPD), in Canada."

Canadian regulatory • Asthma • Chronic Obstructive Pulmonary Disease • Respiratory Diseases

Modeling of pulmonary deposition of agents of open and fixed dose triple combination therapies through two different low-resistance inhalers in COPD: a pilot study. (PubMed, Front Med (Lausanne)) - "Spiriva Respimat showed significantly higher PD and lower ETD values in all COPD patients and Controls compared with the two pMDIs. For Foster pMDI and Trimbow pMDI similar PD were observed in Controls, while ETD between Controls and AE-COPD patients did significantly differ...Our study is the first to model and compare PD using pMDIs and an SMI as triple combination in COPD. In conclusion, switching from FDC to open triple therapy in cases when adherence to devices is maintanined may contribute to better therapeutic effectiveness in individual cases using low resistance inhalers."

Combination therapy • Journal • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases

Lupin's Generic Spiriva Launch Delayed As FDA Action Expected By August (Generics Bulletin - Informa) - "Lupin has pushed the US launch for a generic to Boehringer’s blockbuster COPD drug Spiriva to September as FDA action is now expected 'latest by August'. Meanwhile, an acquisition of Medisol in France and ANDA submissions in the US are part of an ongoing focus on injectables."

Generic launch • PDUFA date • Asthma • Chronic Obstructive Pulmonary Disease • Respiratory Diseases

Reducing carbon footprint by switching to reusable soft-mist inhalers. (PubMed, ERJ Open Res) - "Over 5 years and across all countries, replacing LAMA inhalers with Spiriva Respimat Reusable reduced COe emissions by 13.3-50.9%, saving 93-6228 tonnes of COe in the different countries studied. Replacing LAMA/LABA inhalers with Spiolto Respimat Reusable reduced COe emissions by 9.5-92.6%, saving 31-50 843 tonnes of COe...Sensitivity analyses showed that results were sensitive to changes in several parameters including varying assumptions around reusability of inhalers and potential COe impact. Replacement of pMDIs and DPIs with Respimat Reusable within the same therapeutic class would result in substantial reductions in COe emissions."

Journal • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases

Tiotropium Handihaler vs. Tiotropium Respimat in COPD (clinicaltrials.gov) - P2 | N=25 | Not yet recruiting | Sponsor: Duke University

New P2 trial • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases

A Case of Recurrent Idiopathic Anaphylaxis While on High-dose Antihistamine Therapy (ACAAI 2022) - "We present a case of malignant IA complicated by severe asthma refractory to high dose antihistamine, prednisone, and Omalizumab...He required high doses of epinephrine during anaphylactic episodes and continued to have anaphylactic episodes despite high-dose antihistamine therapy and prednisone...Furthermore, the patient's asthma is not controlled despite optimal therapy with Symbicort and Spiriva Respimat. Due to his poor asthma control he may benefit from Dupilumab as a second biologic...Discussion Our case adds to sparse literature on malignant IA complicated by severe asthma. Off label trials of two biologics may be warranted when dealing with treatment failure in such settings."

Clinical • Asthma • Carcinoid Tumor • Cardiovascular • Complement-mediated Rare Disorders • Endocrine Cancer • Hereditary Angioedema • Immunology • Neuroendocrine Tumor • Oncology • Pulmonary Disease • Respiratory Diseases • Solid Tumor • IL4

Inhaled Long-acting Bronchodilators With or Without Inhaled Glucocorticosteroids for Preventing Hospitalizations and Death in Elderly Patients With Chronic Obstructive Pulmonary Disease (clinicaltrials.gov) - P4 | N=843 | Terminated | Sponsor: Università degli Studi di Ferrara | Trial completion date: Mar 2023 ➔ Oct 2022 | Recruiting ➔ Terminated; Contract terminated between AIFA and the Sponsor (University of Ferrara)

Trial completion date • Trial termination • Chronic Obstructive Pulmonary Disease • Congestive Heart Failure • Immunology • Pulmonary Disease • Respiratory Diseases

Regular Use Tiotropium and Tolerance to Bronchoprotection in Mild Asthma (clinicaltrials.gov) - P4 | N=12 | Completed | Sponsor: University of Saskatchewan | Not yet recruiting ➔ Completed

Trial completion • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

NIS PIRATE: Assessment of Health-related Quality of Life After Switching COPD Patients From a Dry Powder Inhaler to a Soft Mist Inhaler Remaining on the Same Inhalative Drug (clinicaltrials.gov) - P=N/A | N=270 | Not yet recruiting | Sponsor: Boehringer Ingelheim

Clinical data • HEOR • New trial • Real-world evidence • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases

INTUITIVE: Description of the Ability to Learn How to Handle Inhaler Devices in COPD (clinicaltrials.gov) - P4 | N=24 | Completed | Sponsor: University Hospital, Bordeaux | Not yet recruiting ➔ Completed

Trial completion • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases

A Study on Whether Patients Prefer the Spiriva® Respimat® or the Spiriva® Handihaler® for Treating Their Chronic Obstructive Pulmonary Disease (COPD) (clinicaltrials.gov) - P4; N=72; Completed; Sponsor: Boehringer Ingelheim; Active, not recruiting ➔ Completed; Trial primary completion date: Jan 2022 ➔ Oct 2021

Clinical • Trial completion • Trial primary completion date • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases

A Study on Whether Patients Prefer the Spiriva® Respimat® or the Spiriva® Handihaler® for Treating Their Chronic Obstructive Pulmonary Disease (COPD) (clinicaltrials.gov) - P4; N=72; Active, not recruiting; Sponsor: Boehringer Ingelheim; Recruiting ➔ Active, not recruiting

Clinical • Enrollment closed • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases

Regular Use Tiotropium and Tolerance to Bronchoprotection in Mild Asthma (clinicaltrials.gov) - P4; N=15; Not yet recruiting; Sponsor: University of Saskatchewan

New P4 trial • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

Inhaled Long-acting Bronchodilators With or Without Inhaled Glucocorticosteroids for Preventing Hospitalizations and Death in Elderly Patients With Chronic Obstructive Pulmonary Disease (clinicaltrials.gov) - P4; N=1032; Recruiting; Sponsor: Università degli Studi di Ferrara; Trial completion date: Mar 2022 ➔ Mar 2023; Trial primary completion date: Oct 2021 ➔ Oct 2022

Clinical • Trial completion date • Trial primary completion date • Chronic Obstructive Pulmonary Disease • Congestive Heart Failure • Immunology • Pulmonary Disease • Respiratory Diseases

Tiotropium Efficacy Against Allergen Induced Early Asthmatic Responses (clinicaltrials.gov) - P4; N=15; Completed; Sponsor: University of Saskatchewan; Recruiting ➔ Completed

Clinical • Trial completion • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

"@Boehringer You need your bottom spanked for your latest Spiriva Respimat (Tiotropium) cartridge inhaler set-up." (@meldiogenes)

[VIRTUAL] Effect of Ensifentrine on Lung Function and Health-Related Quality of Life (QoL) by COPD Severity: Analysis from a Phase 2b Dose Ranging Study (ATS 2021) - "This sub-analysis demonstrated that severe patients showed similar absolute improvements in lung function as patients with more moderate impairment, which translates into a higher relative improvement in lung function in severe COPD patients relative to their baseline lung function. Improvements in both sub-groups were clinically meaningful after 4 weeks of treatment."

Clinical • HEOR • P2b data • Chronic Obstructive Pulmonary Disease • Immunology • Respiratory Diseases

[VIRTUAL] Safety of Dual PDE3/4 Inhibitor Ensifentrine Added to Tiotropium: Gastrointestinal and Cardiovascular Adverse Events from a Four-Week Randomized, Controlled Trial (ATS 2021) - "Gastrointestinal and cardiac disorders were rare with ensifentrine and there were no deaths. There were no clinically meaningful changes from baseline in ECG or vital signs parameters over the 4-week treatment period."

Adverse events • Clinical • Atrial Fibrillation • Cardiovascular • Chronic Obstructive Pulmonary Disease • Gastroesophageal Reflux Disease • Gastrointestinal Disorder • Immunology • Myocardial Infarction • Respiratory Diseases